

Subpart D—Testing Procedures**§ 355.70 Testing procedures for fluoride dentifrice drug products.**

(a) A fluoride dentifrice drug product shall meet the biological test requirements for animal caries reduction and one of the following tests: Enamel solubility reduction or fluoride enamel uptake. The testing procedures for these biological tests are labeled *Biological Testing Procedures for Fluoride Dentifrices*; these testing procedures are on file under Docket No. 80N-0042 in the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and are available on request to that office.

(b) The United States Pharmacopeia fluoride dentifrice reference standards along with reference standard stability profiles (total fluoride, available fluoride ion, pH, and specific gravity) required to be used in the biological tests are available to any purchaser upon written request to the United States Pharmacopeial Convention, Inc., 1260 Twinbrook Parkway, Rockville, MD 20852.

(c) Alternative testing procedures may be used. Any proposed modification or alternative testing procedures shall be submitted as a petition in accord with § 10.30 of this chapter. The petition should contain data to support the modification or data demonstrating that an alternative testing procedure provides results of equivalent accuracy. All information submitted will be subjected to the disclosure rules in part 20 of this chapter.

PART 357—MISCELLANEOUS INTERNAL DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE**Subpart A [Reserved]****Subpart B—Anthelmintic Drug Products**

Sec.

357.101 Scope.

357.103 Definition.

357.110 Anthelmintic active ingredient.

357.150 Labeling of anthelmintic drug products.

357.152 Package inserts for anthelmintic drug products.

357.180 Professional labeling.

Subpart C—Cholecystokinetic Drug Products

357.201 Scope.

357.203 Definition.

357.210 Cholecystokinetic active ingredients.

357.250 Labeling of cholecystokinetic drug products.

357.280 Professional labeling.

Subparts D–H [Reserved]**Subpart I—Deodorant Drug Products for Internal Use**

357.801 Scope.

357.803 Definitions.

357.810 Active ingredients for deodorant drug products for internal use.

357.850 Labeling of deodorant drug products for internal use.

AUTHORITY: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371.

Subpart A [Reserved]**Subpart B—Anthelmintic Drug Products**

SOURCE: 51 FR 27759, Aug. 1, 1986, unless otherwise noted.

§ 357.101 Scope.

(a) An over-the-counter anthelmintic drug product in a form suitable for oral administration is generally recognized as safe and effective and is not misbranded if it meets each condition in this subpart and each general condition established in § 330.1.

(b) References in this subpart to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted.

§ 357.103 Definition.

As used in this subpart:

Anthelmintic. An agent that is destructive to worms.

§ 357.110 Anthelmintic active ingredient.

The active ingredient of the product is pyrantel pamoate when used within the dosage limits established in § 357.150(d)(1).